A review of quantitative diffusion-weighted MR imaging for breast cancer: Towards noninvasive biomarker

Advanced breast diffusion-weighted imaging: what are the next steps? A proposal from the EUSOBI International Breast Diffusion-weighted Imaging working group

OBJECTIVES

This study by the EUSOBI International Breast Diffusion-weighted Imaging (DWI) working group aimed to evaluate the current and future applications of advanced DWI in breast imaging.

METHODS

A literature search and a comprehensive survey of EUSOBI members to explore the clinical use and potential of advanced DWI techniques and a literature search were involved. Advanced DWI approaches such as intravoxel incoherent motion (IVIM), diffusion kurtosis imaging (DKI), and diffusion tensor imaging (DTI) were assessed for their current status and challenges in clinical implementation.

RESULTS

Although a literature search revealed an increasing number of publications and growing academic interest in advanced DWI, the survey revealed limited adoption of advanced DWI techniques among EUSOBI members, with 32% using IVIM models, 17% using non-Gaussian diffusion techniques for kurtosis analysis, and only 8% using DTI. A variety of DWI techniques are used, with IVIM being the most popular, but less than half use it, suggesting that the study identified a gap between the potential benefits of advanced DWI and its actual use in clinical practice.

CONCLUSION

The findings highlight the need for further research, standardization and simplification to transition advanced DWI from a research tool to regular practice in breast imaging. The study concludes with guidelines and recommendations for future research directions and clinical implementation, emphasizing the importance of interdisciplinary collaboration in this field to improve breast cancer diagnosis and treatment.

CLINICAL RELEVANCE STATEMENT

Advanced DWI in breast imaging, while currently in limited clinical use, offers promising improvements in diagnosis, staging, and treatment monitoring, highlighting the need for standardized protocols, accessible software, and collaborative approaches to promote its broader integration into routine clinical practice.

KEY POINTS

Increasing number of publications on advanced DWI over the last decade indicates growing research interest. EUSOBI survey shows that advanced DWI is used primarily in research, not extensively in clinical practice. More research and standardization are needed to integrate advanced DWI into routine breast imaging practice.

Retrospective BReast Intravoxel Incoherent Motion Multisite (BRIMM) multisoftware study

Introduction

The intravoxel incoherent motion (IVIM) model of diffusion weighted imaging (DWI) provides imaging biomarkers for breast tumor characterization. It has been extensively applied for both diagnostic and prognostic goals in breast cancer, with increasing evidence supporting its clinical relevance. However, variable performance exists in literature owing to the heterogeneity in datasets and quantification methods.

Methods

This work used retrospective anonymized breast MRI data (302 patients) from three sites employing three different software utilizing least-squares segmented algorithms and Bayesian fit to estimate 1st order radiomics of IVIM parameters perfusion fraction (fp ), pseudo-diffusion (Dp ) and tissue diffusivity (Dt ). Pearson correlation (r) coefficients between software pairs were computed while logistic regression model was implemented to test malignancy detection and assess robustness of the IVIM metrics.

Results

Dt and fp maps generated from different software showed consistency across platforms while Dp maps were variable. The average correlation between the three software pairs at three different sites for 1st order radiomics of IVIM parameters were Dtmin/Dtmax/Dtmean/Dtvariance/Dtskew/Dtkurt: 0.791/0.891/0.98/0.815/0.697/0.584; fpmax/fpmean/fpvariance/fpskew/fpkurt: 0.615/0.871/0.679/0.541/0.433; Dpmax/Dpmean/Dpvariance/Dpskew/Dpkurt: 0.616/0.56/0.587/0.454/0.51. Correlation between least-squares algorithms were the highest. Dtmean showed highest area under the ROC curve (AUC) with 0.85 and lowest coefficient of variation (CV) with 0.18% for benign and malignant differentiation using logistic regression. Dt metrics were highly diagnostic as well as consistent along with fp metrics.

Discussion

Multiple 1st order radiomic features of Dt and fp obtained from a heterogeneous multi-site breast lesion dataset showed strong software robustness and/or diagnostic utility, supporting their potential consideration in controlled prospective clinical trials.

Histogram analysis of intravoxel incoherent motion imaging: Correlation with molecular prognostic factors and combined subtypes of breast cancer

PURPOSE

To look for links between diffusion and IVIM parameters and different molecular subtypes and prognostic factors through histogram analysis.

MATERIALS AND METHODS

A total of 139 patients with breast cancer who had pre-operative MRI examinations were enrolled in this retrospective study. Histograms of the diffusion and IVIM parameters were analyzed for the whole tumor, and an association was investigated between the parameters and the different molecular prognostic factors and subtypes using the nonparametric test, Spearman's rank correlation, and receiver operating characteristic (ROC) curve.

RESULTS

The histogram metrics of the diffusion and IVIM parameters were significantly different for molecular prognostic factors such as human epidermal receptor factor-2 (HER2), progesterone receptor, estrogen receptor, and ki-67. All histogram metrics displayed a poor correlation with all groups (r = -0.28-0.29). There were significant differences in the histogram metrics for the Luminal B-HER2 (-) vs. HER2-positive (non-luminal) subtypes in the mean and 10th percentile D, with the area under the curves (AUCs) of 0.742 and 0.700, respectively, and for the Luminal A and HER2-positive (non-luminal) subtypes in the 90th percentile and entropy of D*, with AUCs of 0.769 and 0.727, respectively.

CONCLUSION

The histogram metrics of IVIM parameters exhibited links with breast cancer prognosis factors and combined subtypes.

Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8+ T cell infiltration

Introduction: Cancer biomarkers are substances or processes highly associated with the presence and progression of cancer, which are applicable for cancer screening, progression surveillance, and prognosis prediction in clinical practice. In our previous studies, we discovered that cancer cells upregulate inositol 1,4,5-triphosphate receptor-interacting protein-like 1 (ITPRIPL1), a natural CD3 ligand, to evade immune surveillance and promote tumor growth. We also developed a monoclonal ITPRIPL1 antibody with high sensitivity and specificity. Here, we explored the application of anti-ITPRIPL1 antibody for auxiliary diagnosis of non-small cell lung cancer (NSCLC). Methods: NSCLC patient tissue samples (n = 75) were collected and stained by anti-ITPRIPL1 or anti-CD8 antibodies. After excluding the flaked samples (n = 15), we evaluated the expression by intensity (0-3) and extent (0-100%) of staining to generate an h-score for each sample. The expression status was classified into negative (h-score < 20), low-positive (20-99), and high-positive (≥ 100). We compared the h-scores between the solid cancer tissue and stroma and analyzed the correlation between the h-scores of the ITPRIPL1 and CD8 expression in situ in adjacent tissue slices. Results: The data suggested ITPRIPL1 is widely overexpressed in NSCLC and positively correlates with tumor stages. We also found that ITPRIPL1 expression is negatively correlated with CD8 staining, which demonstrates that ITPRIPL1 overexpression is indicative of poorer immune infiltration and clinical prognosis. Therefore, we set 50 as the cutoff point of ITPRIPL1 expression H scores to differentiate normal and lung cancer tissues, which is of an excellent sensitivity and specificity score (100% within our sample collection). Discussion: These results highlight the potential of ITPRIPL1 as a proteomic immunohistochemical NSCLC biomarker with possible advantages over the existing NSCLC biomarkers, and the ITPRIPL1 antibody can be applied for accurate diagnosis and prognosis prediction.